Xvivo Perfusion AB (FRA:3XV) Net Income From Continuing Operations : €9.58 Mil (TTM As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Xvivo Perfusion AB Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Xvivo Perfusion AB's net income from continuing operations for the three months ended in Mar. 2024 was €2.65 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Mar. 2024 was €9.58 Mil.

Xvivo Perfusion AB Net Income From Continuing Operations Historical Data

The historical data trend for Xvivo Perfusion AB's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Xvivo Perfusion AB Net Income From Continuing Operations Chart

Xvivo Perfusion AB Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Net Income From Continuing Operations

Get a 7-Day Free Trial

0.51

-5.63

0.65

2.03

8.45

Xvivo Perfusion AB Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Net Income From Continuing Operations	Get a 7-Day Free Trial															1.48	0.98	0.08	5.86	2.65

Xvivo Perfusion AB Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €9.58 Mil.

Xvivo Perfusion AB (FRA:3XV) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Xvivo Perfusion AB (FRA:3XV) » Definitions » Net Income From Continuing Operations

Comparable Companies

Traded in Other Exchanges

XVIPF:USA XVIVO:Sweden

Address

Massans gata 10, P.O. Box 53015, Gothenburg, SWE, SE-400 14

Website

https://www.xvivoperfusion.com

Xvivo Perfusion AB is a medical technology company dedicated to extending the life of all major organs so transplant teams around the world can save more lives. Its solutions allow clinicians and researchers to push the boundaries of transplantation medicine. It operates in three segments namely, Thoracic: Sales of lung and heart transplant products, Abdominal: Sales of liver and kidney transplant products. Services: Revenue from sales of services in organ recovery (carried out by subsidiary STAR Teams Inc.). The majority of revenue is derived from the Thoracic segment. Geographically, the majority is from the United States.

Xvivo Perfusion AB (FRA:3XV) Headlines

No Headlines